New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Elevated low-density lipoprotein cholesterol (LDL-C) is a principally modifiable cause of atherosclerotic cardiovascular disease; accordingly, recent European and US multisociety dyslipidaemia guidelines emphasise the importance of lowering LDL-C to reduce cardiovascular risk. This review provides p...

Celý popis

Podrobná bibliografia

Vydané v:	Atherosclerosis Ročník 319; s. 51 - 61
Hlavní autori:	Atar, Dan, Jukema, J. Wouter, Molemans, Bart, Taub, Pam R., Goto, Shinya, Mach, François, CerezoOlmos, Cesar, Underberg, James, Keech, Anthony, Tokgözoğlu, Lale, Bonaca, Marc P.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Ireland Elsevier B.V 01.02.2021
Predmet:	Cardiovascular risk Dyslipidaemia Guidelines Lipid-lowering therapy Low-density lipoprotein cholesterol Secondary prevention Secondary prevention Dyslipidaemia Lipid-lowering therapy Low-density lipoprotein cholesterol Cardiovascular risk Guidelines
ISSN:	0021-9150, 1879-1484, 1879-1484
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!